Immunome (IMNM) EBIAT (2023 - 2025)
Immunome's EBIAT history spans 3 years, with the latest figure at -$69.9 million for Q4 2025.
- For Q4 2025, EBIAT rose 12.9% year-over-year to -$69.9 million; the TTM value through Dec 2025 reached -$212.4 million, up 27.5%, while the annual FY2025 figure was -$212.4 million, 27.5% up from the prior year.
- EBIAT reached -$69.9 million in Q4 2025 per IMNM's latest filing, down from -$57.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$4.3 million in Q1 2023 to a low of -$129.5 million in Q1 2024.
- Average EBIAT over 3 years is -$51.0 million, with a median of -$45.2 million recorded in 2024.
- Peak YoY movement for EBIAT: crashed 2932.6% in 2024, then surged 67.84% in 2025.
- A 3-year view of EBIAT shows it stood at -$92.6 million in 2023, then increased by 13.37% to -$80.2 million in 2024, then increased by 12.9% to -$69.9 million in 2025.
- Per Business Quant, the three most recent readings for IMNM's EBIAT are -$69.9 million (Q4 2025), -$57.5 million (Q3 2025), and -$43.4 million (Q2 2025).